4,628 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Pettinga Financial Advisors LLC

Pettinga Financial Advisors LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 4,628 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Weybosset Research & Management LLC lifted its holdings in shares of Pfizer by 2.0% in the second quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock worth $557,000 after acquiring an additional 250 shares during the last quarter. Congress Asset Management Co. MA lifted its holdings in shares of Pfizer by 2.0% in the fourth quarter. Congress Asset Management Co. MA now owns 13,235 shares of the biopharmaceutical company’s stock worth $578,000 after acquiring an additional 254 shares during the last quarter. D.B. Root & Company LLC lifted its holdings in shares of Pfizer by 0.7% in the fourth quarter. D.B. Root & Company LLC now owns 36,078 shares of the biopharmaceutical company’s stock worth $1,575,000 after acquiring an additional 255 shares during the last quarter. Cottage Street Advisors LLC lifted its holdings in shares of Pfizer by 4.0% in the fourth quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 255 shares during the last quarter. Finally, Financial Gravity Wealth Inc. lifted its holdings in shares of Pfizer by 33.2% in the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 257 shares during the last quarter. 71.81% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on the company. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. Morgan Stanley downgraded Pfizer from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $48.00 to $40.00 in a research note on Tuesday, July 30th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a research note on Monday. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Fourteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $46.56.



Pfizer stock opened at $34.66 on Friday. The business has a 50 day moving average of $41.01 and a 200-day moving average of $41.72. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.27. The company has a market capitalization of $194.69 billion, a P/E ratio of 11.55, a P/E/G ratio of 2.81 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. The business had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.8 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 4.16%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s dividend payout ratio is presently 48.00%.

In other Pfizer news, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the sale, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Frank A. Damelio sold 153,184 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Why do companies issue convertible shares?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.